Strategies for physician education in therapeutic drug monitoring.

Although therapeutic drug monitoring (TDM) is probably very useful overall, studies suggest that it could be used better. Many drug concentrations appear to have inappropriate indications or suboptimal timing, particularly in the inpatient setting. Undermonitoring is also a concern. Thus, it may be possible to both improve the quality of TDM and reduce the overall costs of care. Here we review approaches for improving the use of TDM and present some illustrative experiences. Specific approaches discussed include use of traditional approaches such as lectures and newsletters, multidisciplinary quality improvement efforts, formal TDM services, and use of the computer as a tool for education and behavior change. Computerized methods appear to hold substantial potential, particularly as more organizations develop better information systems, but other approaches are also effective and are complementary. To be most successful, interventions should consider all stages of the process.

[1]  P. Lietman,et al.  Serum vancomycin concentrations: reappraisal of their clinical value. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J H Harrison,et al.  Identification of patients for pharmacologic review by computer analysis of clinical laboratory drug concentration data. , 1995, American journal of clinical pathology.

[3]  D W Bates,et al.  Evaluating the appropriateness of digoxin level monitoring. , 1999, Archives of internal medicine.

[4]  Gordon H. Guyatt,et al.  Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. , 1993, JAMA.

[5]  D W Bates,et al.  Appropriateness of antiepileptic drug level monitoring. , 1995, JAMA.

[6]  S B Soumerai,et al.  Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. , 1984, The Milbank Memorial Fund quarterly. Health and society.

[7]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[8]  Jonathan M. Teich,et al.  Potential identifiability and preventability of adverse events using information systems. , 1994, Journal of the American Medical Informatics Association : JAMIA.

[9]  F. Bochner,et al.  Therapeutic Drug Monitoring and Patient Outcome , 1994, Clinical pharmacokinetics.

[10]  L. Ried,et al.  Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. , 1989, American journal of hospital pharmacy.

[11]  M. Enkin,et al.  Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. , 1989, The New England journal of medicine.

[12]  J M Teich,et al.  Computerized physician order entry and quality of care. , 1994, Quality management in health care.

[13]  Thomas Lee,et al.  Critical Pathways as a Strategy for Improving Care: Problems and Potential , 1995, Annals of Internal Medicine.

[14]  William W. Stead,et al.  Review: Computer-based Physician Order Entry: The State of the Art , 1994, J. Am. Medical Informatics Assoc..

[15]  M. Raebel,et al.  Vancomycin Therapeutic Drug Monitoring: Is it Necessary? , 1993, The Annals of pharmacotherapy.

[16]  N. Saunders Why monitor peak vancomycin concentrations? , 1994, The Lancet.

[17]  G. Koren,et al.  Organization and efficacy of a therapeutic drug monitoring consultation service in a pediatric hospital. , 1985, Therapeutic drug monitoring.

[18]  D. Wing,et al.  Impact of a therapeutic drug monitoring program for digoxin. , 1987, Archives of internal medicine.

[19]  C. McDonald,et al.  Physician inpatient order writing on microcomputer workstations. Effects on resource utilization. , 1993, JAMA.

[20]  J. Lomas,et al.  From evidence to practice in the United States, the United Kingdom, and Canada. , 1993, The Milbank quarterly.